The global granulocyte macrophage colony stimulating factor market is anticipated to grow at a significant CAGR 10.8% during the forecast period (2022-2028). Granulocyte macrophage colony-stimulating factor, also called as CSF2 (colony stimulating factor 2), is a monomeric glycoprotein released by usual killer cells, T cells, mast cells, macrophages, fibroblasts, and endothelial cells that acts as a cytokine. The COVID-19 pandemic has significantly affected the global granulocyte macrophage colony stimulating factor market. Since this factor is a myelopoietic development factor and pro-inflammatory cytokine, it plays a key role in the treatment of immunological disease, lung inflammation, and alveolar macrophage homeostasis. Further, the inhibition as well as administration of granulocyte macrophage colony stimulating factor, both are now being medically tested in COVID-19 clinical trials. 

Other major factors attributable to the market growth includes the increasing prevalence of fungal infections, the rising prevalence of cancer, and the growing cases of failed skin grafting. Apart from COVID-19, the growing cancer cases substantially impact the market growth. North America region is likely to witness a significant growth in the market owing to the rising prevalence of cancer. This influences the market growth in the North American region. On the other side, the exorbitantly high cost of chemotherapy treatments, and side effects associated with the drug may restrain the growth of the global granulocyte macrophage colony stimulating factor market.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Route of Administration

o By Application

o By End-User 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Amgen Inc., Merck KGaA, and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Granulocyte Macrophage Colony Stimulating Factor Market Report by Segment

By Route of Administration

• Subcutaneous Bolus

• Intravenous Infusion

By Application

• Fungal Infections

• Skin Graft

• Cut-Burn Wounds

• Acute Myelogenous Leukemia

• Others

By End-User

• Hospitals and Clinics

• Surgical Centers

• Diagnostic Centers

• Research Centers

• Others

Global Granulocyte Macrophage Colony Stimulating Factor Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa